Equity Research Analysis: Medicus Pharma Ltd. (MDCX)
|Blank Capital Research Unit|Spot: $1.10
Price$1.10
Composite Score30.4/100
RatingAVOID (1★)
Rank#4496 OF 7,333
Market Cap$43M
ROE
IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#4496
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$43M
Raza Bokhari
Medicus Pharma Ltd. is a clinical-stage pharmaceutical company focused on developing and commercializing innovative therapies for unmet medical needs, with an initial focus on dermatological conditions. They are developing a novel microneedle patch technology for targeted drug delivery.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | 28.5% | 8.0% | 100.0% | 100.0% | 10.4% | -4.6% | 3.3% | 0.0x | $141.8B | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | 46.1% | 16.6% | 51.3% | 31.9% | 26.8% | -4.0% | 1.0% | 25.0x | $272.1B | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | 10.3% | 3.1% | 24.1% | 7.2% | 4.7% | 14.3% | 0.8% | 25.0x | $11.4B | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | 2.2% | 1.5% | 9.3% | 5.3% | 2.2% | -8.5% | 2.2% | 16.0x | $18.9B | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 35.5% | 19.8% | 48.7% | 29.2% | 24.7% | 4.4% | 0.8% | 32.0x | $181.9B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | 11.8% | 8.8% | 45.9% | 11.3% | 11.1% | 25.7% | 3.7% | 0.0x | $1.8B | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.6% | 7.0% | 66.5% | 17.1% | 15.6% | 39.0% | 0.0% | 0.0x | $115M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | 22.6% | 4.9% | 71.2% | 12.8% | 9.4% | 1.7% | 5.9% | 124.0x | $72.1B | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | 3.0% | 1.1% | 20.9% | 7.3% | 1.3% | 3.0% | 0.9% | 67.0x | $1.2B | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | 8.2% | 3.5% | 55.3% | 25.9% | 12.4% | 0.7% | 1.7% | 0.0x | $87.0B | VS | |
$MDCX Medicus Pharma Ltd. | 30 | 24 | 54 | 8 | - | - | 3826.2% | -640.7% | - | -0.1% | -138103.3% | - | 0.0% | 105.0x | $43M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -2.5% | -0.1% | 42.5% | 1.3% | -0.2% | 5.9% | 0.0% | 0.2x | - | REF |
Medicus Pharma Ltd. (MDCX) receives a "Avoid" rating with a composite score of 30.4/100. It ranks #4496 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
Lagging peers — losers tend to keep underperforming
Fair valuation relative to peers
Weak fundamentals — higher risk of value trap
Average volatility — neutral timing signal
Aggressive spending — empire-building risk, dilutive growth
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for MDCX.
View All RatingsROE proxy 3826.2% (sector -2.5%)
GM N/A vs sector 43%, OM -0% vs sector 1%
Capital turnover N/A, R&D intensity 9947.6%
Rev growth N/A, 2yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate Medicus Pharma Ltd. (MDCX) as Avoid with a composite score of 30.4/100 at a current price of $1.10. The stock falls in the bottom quintile, and the multi-factor weakness suggests a high probability of continued underperformance.
Medicus Pharma Ltd. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 30.4/100 places it at rank #4496 in our full universe.
Narrow
High
Poor
Fair Value
Returns on equity of 3826.2% exceed cost of capital.
Stable competitive position in a defensive sector.
Leverage of 105% D/E amplifies downside risk.
Weak momentum suggests persistent institutional selling pressure.
Below-average quality raises earnings sustainability concerns.
Medicus Pharma Ltd. represents a avoid based on multi-factor quantitative performance.
Our quantitative model flags Medicus Pharma Ltd. with an Avoid rating, assigning a composite score of 30.4/100 and 1 out of 5 stars. Ranked #4496 of 7,333 stocks, MDCX falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
Medicus Pharma Ltd. registers a weak quality score of just 24/100, indicating significant profitability challenges. The company reports a return on equity of 3826.2% (sector avg: -2.5%), net margins of -138103.3% (sector avg: -0.2%). Low quality scores are often associated with businesses in turnaround mode, early-stage growth, or structurally challenged industries.
MDCX's value score of 54/100 indicates the stock is fairly valued based on its current fundamentals. Key valuation metrics include a P/B ratio of 6.69x. At this level, neither a clear bargain nor overpriced, the stock's attractiveness depends more on forward growth expectations and qualitative factors.
Medicus Pharma Ltd.'s investment score of 25/100 suggests limited reinvestment activity. Key growth metrics include a return on assets of -640.7% (sector: -0.1%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
Medicus Pharma Ltd. is experiencing notably weak momentum with a score of just 8/100. The stock has underperformed its peers and is trending below major moving averages. Revenue growth data is not currently available, while a beta of 0.30 reflects its sensitivity to broader market moves. While deep momentum weakness can occasionally present value opportunities, it often reflects deteriorating fundamentals or structural headwinds that may persist.
MDCX's stability score of 40/100 signals elevated volatility and/or leverage concerns. Key stability metrics include a beta of 0.30 and a debt-to-equity ratio of 105.00x (sector avg: 0.2x). Investors should be prepared for wider-than-average price swings and consider position sizing accordingly to manage portfolio risk.
Medicus Pharma Ltd.'s short interest score of 33/100 reveals significant bearish positioning, suggesting institutional investors are actively betting against the stock. Specific risk factors include elevated leverage (D/E: 105.00x), micro-cap liquidity risk. At $43M (micro-cap), MDCX carries meaningful risk and is best suited for investors with high risk tolerance who have thoroughly evaluated the bear thesis.
Medicus Pharma Ltd. is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #4496 of 7,333 overall (39th percentile). Key comparisons include ROE of 3826.2% exceeding the -2.5% sector median and operating margins of -0.1% below the 1.3% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While MDCX currently exhibits a AVOID profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Momentum (8) would have the largest impact on the composite score.
ROE 154381% BELOW SECTOR MEDIAN
Op. Margin 110% BELOW SECTOR MEDIAN
Debt/Equity 52400% ABOVE SECTOR MEDIAN
Above 50MA
37.18%
Net New Highs
+51081
Medicus Pharma (NASDAQ:MDCX) CEO Raza Bokhari talked with Proactive about the FDA's clearance to begin a Phase 2b dose optimization study for Teverelix, the company’s next-generation GnRH antagonist targeting advanced prostate cancer. Proactive: All right. Welcome back inside our Proactive...
Medicus Pharma (NASDAQ:MDCX) announced that it has received “study may proceed” clearance from the US Food and Drug Administration (FDA) to initiate a Phase 2b dose-optimization study of Teverelix, its investigational long-acting gonadotropin-releasing hormone (GnRH) antagonist, in men with...
NEW YORK CITY, NY / ACCESS Newswire / February 10, 2026 /New to The Street, the nationally syndicated, long-form television and digital media platform, today announced it has signed a six-part media series with Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" ...
Dr. Raza Bokhari, Exec Chairman & CEO, Interviewed by Bloomberg Open Interest Anchor Matt Miller PHILADELPHIA, PA / ACCESS Newswire / February 12, 2026 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided biotech/life ...